Price
chg
chg neg
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
low api
52 wk hi
high api
Cash
$264.5 M
Burn Rate (Qtr)
$29.3 M
Mkt Cap
mkt cap api
Avg Volume
volume api
*cash/burn updated:
Q2 '21
Drug Pipeline
Click on drug name or indication to see upcoming trial info, prior data, and more general information.
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
TRIL
Company Profile
TRIL was acquired by Pfizer on 11/17/21
Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective “do not eat” signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this “do not eat” signal with decoy receptors, we aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.
Recent Posts
See what the community is saying - click to see full post.